Refractory hypokalemia in a patient on levetiracetam: An under-recognized clinical association

M. Yathwin Kanagavel, Venkata Shashank Davuluri, V. Vivek · 2026

Read Refractory hypokalemia in a patient on levetiracetam: An under-recognized clinical association by M. Yathwin Kanagavel, Venkata Shashank Davuluri, V. Vivek (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610750.txt.

Description

Kanagavel, Davuluri, and Vivek report an unusual side effect of a common seizure drug, in this 2026 case report. The drug, levetiracetam, is a first choice for preventing seizures because it is gentle on the body and clashes with few other medicines. Their patient was a fifty-six-year-old man admitted with a severe brain injury after a road accident. He was given the drug to prevent seizures, since one may have occurred at the scene.

Four days into treatment, his blood potassium fell and stayed low despite replacement, a state called refractory hypokalemia. Low potassium is dangerous for the heart and muscles, and it is rarely blamed on this drug. The authors walk through the case and the checks that pointed to the medicine as the cause. Their aim is to put an under-recognized pairing on doctors' radar before a routine drug choice turns risky.

Catalog record

CREATORM. Yathwin Kanagavel, Venkata Shashank Davuluri, V. Vivek
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13610750

Browse the full library · About the Tower of Babel